The discovery of the ALT pathway in pancreatic neuroendocrine tumors provides a critical prognostic biomarker, helping identify patients at higher risk of relapse. This insight enables more personalized monitoring and treatment strategies to improve patient outcomes and was deployed to the clinic in 2025.